Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

The AdventHealth Neuroscience Institute is testing IDP-023 for primary or nonactive secondary progressive multiple sclerosis ...

Since its launch, Ocrevus has set a new standard of care in MS and is the most prescribed disease modifying therapy in the United States with more than 400,000 people treated globally. With the ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...

Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS ...

FRANKFURT, April 2 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the ...